Key result
A higher R2CHA2DS2-VA score was significantly associated with worse 90-day functional outcomes in acute ischemic stroke patients treated with endovascular thrombectomy (OR 1.637; 95% CI 2.436-5.510; P<0.001).
Why the study?
The predictive value of pre-stroke CHA2DS2-VA, R2CHA2DS2-VA, CHA2DS2-VASc, and R2CHA2DS2-VASc scores for 90-day functional outcomes after endovascular treatment in acute ischemic stroke had not been evaluated.
Does the R2CHA2DS2-VA score predict 90-day functional outcomes in patients with acute ischemic stroke undergoing endovascular thrombectomy?
Cohort (n=583)
No
Does the R2CHA2DS2-VA score predict 90-day functional outcomes in patients with acute ischemic stroke undergoing endovascular thrombectomy?
Odds Ratio: 1.637 (95% CI 2.436–5.51)
p-value: p=<0.001
The R2CHA2DS2-VA score is a superior predictor of 90-day functional outcomes in acute ischemic stroke patients treated with endovascular thrombectomy compared to other CHA2DS2-VASc-based scores.
R2CHA2DS2-VA may refine post-EVT outcome prediction; hypothesis-generating and requires prospective validation before clinical use.
Background and Objectives: Endovascular treatment (EVT) has been shown to enhance long-term recovery and lower mortality rates in patients with intracranial large vessel occlusion-associated acute ischemic strokes (AISs).We aimed to evaluate the predictive value of the pre-stroke CHA2DS2-VA, R2CHA2DS2-VA, CHA2DS2-VASc, and R2CHA2DS2-VASc scores in determining 90-day functional outcomes based on the modified Rankin Scale (mRS). Methods: In a single center between 2018 and 2023, 665 AIS patients who underwent EVT and achieved successful reperfusion were screened retrospectively. After inclusion and exclusion criteria, 583 patients were included. Based on 90-day mRS scores, patients were classified into two groups: good (mRS ≤ 2, n = 257) and poor functional outcomes (mRS 3–6, n = 326). The pre-stroke scores were calculated. Results: When ROC curve analysis was performed, R2CHA2DS2-VA demonstrated the highest AUC value (p = 0.0443) among these scores. The optimal cutoff score was determined to be 4, yielding a sensitivity of 75.77% and specificity of 93.39%. In multivariable analysis, a higher R2CHA2DS2-VA score was significantly associated with worse outcomes (OR = 1.637, 95%, CI: 2.436–5.510, p < 0.001). A longer onset-to-recanalization time (OR = 1.009, 95%, CI: 1.005–1.014, p < 0.001) and presence of hyperlipidemia (OR = 2.960, 95%, CI: 1.254–6.988, p = 0.01) were correlated with poor prognosis. Higher baseline NIHSS scores were associated with unfavorable outcomes (OR = 1.201, 95%, CI: 1.014–1.422, p = 0.034), and this association remained significant for NIHSS scores measured 24 h post-EVT (OR = 1.467, 95%, CI: 1.230–1.748, p < 0.001). Conclusions: The R2CHA2DS2-VA score demonstrates superior predictive ability for 90-day functional outcomes in AIS patients treated with EVT, surpassing CHA2DS2-VASc and similar scoring systems.
No takes yet. Share an insight, caveat, or question.
Boyacı et al. (2025) conducted a cohort in Acute ischemic stroke (n=583). R2CHA2DS2-VA score vs. Lower R2CHA2DS2-VA score was evaluated on Poor 90-day functional outcomes (mRS 3-6) (OR 1.637, 95% CI 2.436-5.510, p=<0.001). A higher R2CHA2DS2-VA score was significantly associated with worse 90-day functional outcomes in acute ischemic stroke patients treated with endovascular thrombectomy (OR 1.637; 95% CI 2.436-5.510; P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: